Gilteritinib (Xospata)
Revision as of 18:49, 29 November 2018 by Jwarner (talk | contribs) (Jwarner moved page Gilteritinib (ASP2215) to Gilteritinib (Xospata): FDA approval)
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Also known as
- Code name: ASP2215
- Brand name: Xospata